{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:49:04Z","timestamp":1790995744849,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Hereditary angioedema (HAE) in patients with normal C1 inhibitor (C1-INH) and the c.988A\u2009&gt;\u2009G (p.Lys330Glu; p.K330E) variant in the plasminogen gene (HAE-PLG) is associated with skin swellings, abdominal pain attacks, and the risk of asphyxiation due to upper airway obstruction. Aim of this observational, retrospective study is to report about the efficacy of various treatments for acute attacks and long-term prophylaxis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The study included 111 patients with HAE-PLG. Thirteen patients were treated with icatibant for 201 acute swelling attacks. The mean duration of the treated attacks (mean 4.3\u2009h; standard deviation [SD] 2.6\u2009h) was significantly shorter than that of the previous 149 untreated attacks (mean 44.7\u2009h; SD 28.6\u2009h, <jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.0001). Twelve patients were treated with plasma-derived C1-INH for 74 acute swelling attacks. The duration of the treated attacks (mean 31.5\u2009h; SD 18.6\u2009h) was significantly shorter than that of the previous 129 untreated in the same patients (mean 48.2\u2009h; SD 32.5\u2009h, <jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.0001). Corticosteroids alone showed good response in 61\/268 attacks (8 patients), low response in 82\/268 attacks (7 patients), and no response in 125\/268 attacks (26 patients). Corticosteroids combined with antihistamines showed good response in 13\/309 attacks (4 patients), low response in 150\/309 attacks (7 patients), and no response in 146\/309 attacks (17 patients). Antihistamines alone were ineffective in all 37 attacks of 5 patients. In 2 patients with imminent asphyxiation due to tongue swelling and partial obstruction of the upper airways fresh frozen plasma was used without clinical response. The mean reduction in attack frequency was 46.3% under progestins (6 patients), 93.9% under tranexamic acid (3 patients) and 83.3% under danazol (3 patients).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>For patients with HAE-PLG various treatment options are available, which completely or at least partially reduce attack duration or attack frequency.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-020-1334-8","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T15:07:01Z","timestamp":1581952021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Treatment of patients with hereditary angioedema with the c.988A&gt;G (p.Lys330Glu) variant in the plasminogen gene"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-4577","authenticated-orcid":false,"given":"Konrad","family":"Bork","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenther","family":"Witzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Machnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Hardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"1334_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0002-9343(63)90162-1","volume":"35","author":"VH Donaldson","year":"1963","unstructured":"Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C'1-esterase. Am J Med. 1963;35:37\u201344.","journal-title":"Am J Med"},{"issue":"1","key":"1334_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM198707023170101","volume":"317","author":"D Stoppa-Lyonnet","year":"1987","unstructured":"Stoppa-Lyonnet D, Tosi M, Laurent J, Sobel A, Lagrue G, Meo T. Altered C1 inhibitor genes in type I hereditary angioedema. N Engl J Med. 1987;317(1):1\u20136.","journal-title":"N Engl J Med"},{"issue":"9225","key":"1334_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(00)02483-1","volume":"356","author":"K Bork","year":"2000","unstructured":"Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356(9225):213\u20137.","journal-title":"Lancet"},{"issue":"3","key":"1334_CR4","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1067\/mai.2000.108106","volume":"106","author":"KE Binkley","year":"2000","unstructured":"Binkley KE, Davis A 3rd. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol. 2000;106(3):546\u201350.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1334_CR5","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.bbrc.2006.03.092","volume":"343","author":"G Dewald","year":"2006","unstructured":"Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343(4):1286\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1334_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jaci.2009.03.038","volume":"124","author":"K Bork","year":"2009","unstructured":"Bork K, Wulff K, Hardt J, Witzke G, Staubach P. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol. 2009;124(1):129\u201334.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1334_CR7","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.jaci.2017.05.020","volume":"141","author":"V Bafunno","year":"2018","unstructured":"Bafunno V, Firinu D, D'Apolito M, Cordisco G, Loffredo S, Leccese A, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol. 2018;141(3):1009\u201317.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1334_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/all.13270","volume":"73","author":"K Bork","year":"2018","unstructured":"Bork K, Wulff K, Steinm\u00fcller-Magin L, Braenne I, Staubach-Renz P, Witzke G, et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy. 2018;73(2):442\u201350.","journal-title":"Allergy."},{"issue":"12","key":"1334_CR9","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1111\/all.13869","volume":"74","author":"K Bork","year":"2019","unstructured":"Bork K, Wulff K, Rossmann H, Steinm\u00fcller-Magin L, Braenne I, Witzke G, et al. Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin. Allergy. 2019;74(12):2479\u201381.","journal-title":"Allergy"},{"issue":"6","key":"1334_CR10","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1086\/509899","volume":"79","author":"S Cichon","year":"2006","unstructured":"Cichon S, Martin L, Hennies H, M\u00fcller F, Van Driessche K, Karpushova A, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet. 2006;79(6):1098\u2013104.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"1334_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clim.2011.07.002","volume":"141","author":"K Bork","year":"2011","unstructured":"Bork K, Wulff K, Meinke P, Wagner N, Hardt J, Witzke G. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol. 2011;141(1):31\u20135.","journal-title":"Clin Immunol"},{"issue":"1","key":"1334_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.clim.2013.08.001","volume":"149","author":"N Kiss","year":"2013","unstructured":"Kiss N, Barab\u00e1s E, V\u00e1rnai K, Hal\u00e1sz A, Varga L\u00c1, Proh\u00e1szka Z, et al. Novel duplication in the F12 gene in a patient with recurrent angioedema. Clin Immunol. 2013;149(1):142\u20135.","journal-title":"Clin Immunol"},{"issue":"11","key":"1334_CR13","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1111\/all.13543","volume":"73","author":"A Belb\u00e9zier","year":"2018","unstructured":"Belb\u00e9zier A, Hardy G, Marlu R, Defendi F, Dumestre Perard C, Boccon-Gibod I, et al. Plasminogen gene mutation with normal C1 inhibitor hereditary angioedema: three additional French families. Allergy. 2018;73(11):2237\u20139.","journal-title":"Allergy"},{"issue":"11","key":"1334_CR14","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1111\/all.13550","volume":"73","author":"H Yakushiji","year":"2018","unstructured":"Yakushiji H, Hashimura C, Fukuoka K, Kaji A, Miyahara H, Kaname S, et al. A missense mutation of the plasminogen gene in hereditary angioedema with normal C1 inhibitor in Japan. Allergy. 2018;73(11):2244\u20137.","journal-title":"Allergy"},{"key":"1334_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13223-019-0346-1","volume":"15","author":"DL Bodian","year":"2019","unstructured":"Bodian DL, Vilboux T, Hauser NS. Genotype-first analysis of a generally healthy population cohort supports genetic testing for diagnosis of hereditary angioedema of unknown cause. Allergy Asthma Clin Immunol. 2019;15:32.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1334_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13601-019-0247-x","volume":"9","author":"A Recke","year":"2019","unstructured":"Recke A, Massalme EG, Jappe U, Steinm\u00fcller-Magin L, Schmidt J, Hellenbroich Y, et al. Identification of the recently described plasminogen gene mutation p.Lys330Glu in a family from Northern Germany with hereditary angioedema. Clin Transl Allergy. 2019;9:9.","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"1334_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000453663","volume":"172","author":"P Triggianese","year":"2017","unstructured":"Triggianese P, Guarino MD, Pellicano C, Borzi M, Greco E, Modica S, De Carolis C, Perricone R. Recurrent angioedema: occurrence, features, and concomitant diseases in an Italian single-center study. Int Arch Allergy Immunol. 2017;172(1):55\u201363.","journal-title":"Int Arch Allergy Immunol"},{"issue":"10","key":"1334_CR18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nrd2694","volume":"7","author":"K Bork","year":"2008","unstructured":"Bork K, Yasothan U, Kirkpatrick P. Icatibant. Nat Rev Drug Discov. 2008;7(10):801\u20132.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"1334_CR19","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1056\/NEJMoa0906393","volume":"363","author":"M Cicardi","year":"2010","unstructured":"Cicardi M, Banerji A, Bracho F, Malbr\u00e1n A, Rosenkranz B, Riedl M, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363(6):532\u201341.","journal-title":"N Engl J Med"},{"key":"1334_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/B978-0-12-800100-4.00002-7","volume":"121","author":"AP Kaplan","year":"2014","unstructured":"Kaplan AP, Joseph K. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Adv Immunol. 2014;121:41\u201389.","journal-title":"Adv Immunol"},{"issue":"24","key":"1334_CR21","doi-asserted-by":"crossref","first-page":"11928","DOI":"10.1016\/S0021-9258(18)37875-X","volume":"263","author":"L Miles","year":"1988","unstructured":"Miles L, Dahlberg C, Plow E. The cell-binding domains of plasminogen and their function in plasma. J Biol Chem. 1988;263(24):11928\u201334.","journal-title":"J Biol Chem"},{"issue":"6","key":"1334_CR22","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1083\/jcb.103.6.2411","volume":"103","author":"E Plow","year":"1986","unstructured":"Plow E, Freaney D, Plescia J, Miles L. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol. 1986;103(6):2411\u201320.","journal-title":"J Cell Biol"},{"issue":"9","key":"1334_CR23","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/blood-2006-04-017350","volume":"108","author":"K Tefs","year":"2006","unstructured":"Tefs K, Gueorguieva M, Klammt J, Allen CM, Aktas D, Anlar FY, et al. Molecular and clinical spectrum of type I plasminogen deficiency: a series of 50 patients. Blood. 2006;108(9):3021\u20136.","journal-title":"Blood."},{"issue":"12","key":"1334_CR24","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1111\/j.1538-7836.2007.02776.x","volume":"5","author":"V Schuster","year":"2007","unstructured":"Schuster V, H\u00fcgle B, Tefs K. Plasminogen deficiency. J Thromb Haemost. 2007;5(12):2315\u201322.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"1334_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12016-016-8544-9","volume":"51","author":"K Bork","year":"2016","unstructured":"Bork K. A decade of change: recent developments in pharmacotherapy of hereditary angioedema (HAE). Clin Rev Allergy Immunol. 2016;51(2):183\u201392.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"1334_CR26","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/cea.12055","volume":"43","author":"C Saule","year":"2013","unstructured":"Saule C, Boccon-Gibod I, Fain O, Kanny G, Plu-Bureau G, Martin L, et al. Benefits of progestin contraception in non-allergic angioedema. Clin Exp Allergy. 2013;43(4):475\u201382.","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"1334_CR27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/all.13076","volume":"72","author":"K Bork","year":"2017","unstructured":"Bork K, Wulff K, Witzke G, Hardt J. Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII). Allergy. 2017;72(2):320\u20134.","journal-title":"Allergy"},{"issue":"1","key":"1334_CR28","first-page":"129","volume":"120","author":"J Kleniewski","year":"1992","unstructured":"Kleniewski J, Blankenship DT, Cardin AD, Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med. 1992;120(1):129\u201339.","journal-title":"J Lab Clin Med"},{"key":"1334_CR29","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0021-9258(19)45531-2","volume":"247","author":"KN Reddy","year":"1972","unstructured":"Reddy KN, Markus G. Mechanism of activation of human plasminogen by streptokinase. J Biol Chem. 1972;247:1683\u201391.","journal-title":"J Biol Chem"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-1334-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-020-1334-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-1334-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T16:50:35Z","timestamp":1613580635000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-1334-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1334"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-1334-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,17]]},"assertion":[{"value":"29 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of the Landes\u00e4rztekammer Rheinland-Pfalz, 837.413.13 (9098-F). All patients gave their informed consent to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Bork reports speaker fees from CSL Behring and Shire, outside the submitted work. Dr. Machnig is a full-time employee of CSL Behring GmbH, Marburg. The other authors have no other conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}